BioCryst Posts Q1 2026 Results, Maintains Growth Outlook
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from BioCryst ( (BCRX) ) is now available.
BioCryst Pharmaceuticals reported first-quarter 2026 results on May 6, 2026, highlighted by ORLADEYO net revenue of $148.3 million, up 11% year-on-year, or 21% on a comparable basis excluding European revenue, as strong new patient prescriptions underscored continued demand in hereditary angioedema. The company posted a GAAP operating loss of $701.6 million driven by a $697.8 million non-cash in-process R&D charge from its January 23, 2026 acquisition of Astria Therapeutics, but generated a non-GAAP operating profit of $54.2 million and ended the quarter with pro forma liquidity of $330.8 million, including post-quarter proceeds.
BioCryst advanced its pipeline with on-track enrollment in the pivotal ALPHA-ORBIT trial of navenibart for hereditary angioedema and progressed BCX17725 into patient dosing in Part 4 of its Phase 1 trial for Netherton syndrome, while discontinuing development of avoralstat for diabetic macular edema to refocus on rare diseases. The company also signed a European licensing deal for navenibart with an affiliate of Neopharmed Gentili, securing $70 million upfront, eligibility for up to $275 million in milestones and tiered royalties, appointed Sandeep M. Menon as chief research and development officer, and reaffirmed its 2026 revenue and non-GAAP operating expense guidance, signaling confidence in sustained growth and disciplined spending despite acquisition-related accounting charges.
The most recent analyst rating on (BCRX) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on BioCryst stock, see the BCRX Stock Forecast page.
Spark’s Take on BCRX Stock
According to Spark, TipRanks’ AI Analyst, BCRX is a Neutral.
The score is driven primarily by the sharp 2025 financial inflection (profitability and free cash flow) and an attractive low P/E valuation, supported by a constructive earnings call and a balance-sheet-positive European licensing deal. The main offsets are balance-sheet structure risk (negative equity), historical volatility, and only neutral-to-mixed near-term technical momentum.
To see Spark’s full report on BCRX stock, click here.
More about BioCryst
BioCryst Pharmaceuticals, Inc. is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema and other rare diseases. Its flagship product is ORLADEYO, the first oral, once-daily plasma kallikrein inhibitor, and it is advancing a pipeline of oral small molecules and injectable protein therapeutics aimed at first- or best-in-class treatments in niche rare-disease markets.
The company’s strategy centers on rare disease expertise, efficient execution, and disciplined capital allocation, with an emphasis on expanding its hereditary angioedema franchise and related kallikrein-targeted therapies. BioCryst operates globally, relying on partnerships, such as regional licensing deals, to extend its commercial reach while managing costs and focusing internal resources on core R&D and key commercial assets.
Average Trading Volume: 5,153,471
Technical Sentiment Signal: Strong Buy
Current Market Cap: $2.34B
For detailed information about BCRX stock, go to TipRanks’ Stock Analysis page.
